KK

Kiran Kumari

Active Director Director DIN 08268440
DIN 08268440 First appointment Oct 2018 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2018
Shareholding value •••• Premium profile

About Kiran Kumari

Data last updated:

Kiran Kumari is a Director at Clievo Pharmaceuticals Private Limited (since 2018). The company operates in Trading. Clievo Pharmaceuticals Private Limited reported revenue of ₹1.5 Lakh (FY 2024).

DIN 08268440
Primary Designation Director
Industry Trading
First Appointment 29 Oct 2018
Oldest Company Age 8 yrs
Largest company Clievo Pharmaceuticals Private Limited · ₹1.5 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director29 Oct 20182018₹1.5 Lakh (FY 2024)Active

Board colleagues of Kiran Kumari

NameDINCompanyDesignation
Suprabha Bharti08268439Clievo Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Clievo Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Kiran Kumari

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kiran Kumari

Kiran Kumari currently holds 1 directorship: Clievo Pharmaceuticals Private Limited (Director, since 29 Oct 2018, revenue ₹1.5 Lakh (FY 2024)).

Kiran Kumari was first appointed on 29 Oct 2018 as Director at Clievo Pharmaceuticals Private Limited.

The current boards of Kiran Kumari's companies include Suprabha Bharti (Clievo Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available